80% of China’s Clinical Trial Data Fraudulent!

A recent investigation of 1622 new drugs submitted to China’s State Food and Drug Administration (CFDA) has found that 1308 of those applications should be withdrawn for containing fabricated, flawed, or inadequate data from clinical trials. Find out more here. (Source: thebmj, October 2016)

You might also be interested in:

BHE Rebrands Itself as Panalgo In Effort To Empower Pharma,… 08/14/2020
PRMA Consulting Announces New Singapore Office and Virtual Open House 08/11/2020
Data Exchange for Drug Rebate Processing and Contract… 08/31/2020
Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
Program Looks to Address Gaps in COVID-19 Data 04/14/2020
Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020